Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy
10.1371/journal.pone.0148901
Saved in:
Main Authors: | , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
Public Library of Science (PLoS)
2018
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/142662 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
id |
sg-nus-scholar.10635-142662 |
---|---|
record_format |
dspace |
spelling |
sg-nus-scholar.10635-1426622024-04-05T09:00:15Z Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy Wang X.J. Tang T. Farid M. Quek R. Tao M. Lim S.T. Wee H.L. Chan A. PHARMACY 10.1371/journal.pone.0148901 PLoS ONE 11 2 e0148901 2018-05-30T07:08:28Z 2018-05-30T07:08:28Z 2016 Article Wang X.J., Tang T., Farid M., Quek R., Tao M., Lim S.T., Wee H.L., Chan A. (2016). Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy. PLoS ONE 11 (2) : e0148901. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0148901 19326203 http://scholarbank.nus.edu.sg/handle/10635/142662 000370054100070 Public Library of Science (PLoS) Scopus |
institution |
National University of Singapore |
building |
NUS Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NUS Library |
collection |
ScholarBank@NUS |
description |
10.1371/journal.pone.0148901 |
author2 |
PHARMACY |
author_facet |
PHARMACY Wang X.J. Tang T. Farid M. Quek R. Tao M. Lim S.T. Wee H.L. Chan A. |
format |
Article |
author |
Wang X.J. Tang T. Farid M. Quek R. Tao M. Lim S.T. Wee H.L. Chan A. |
spellingShingle |
Wang X.J. Tang T. Farid M. Quek R. Tao M. Lim S.T. Wee H.L. Chan A. Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy |
author_sort |
Wang X.J. |
title |
Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy |
title_short |
Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy |
title_full |
Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy |
title_fullStr |
Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy |
title_full_unstemmed |
Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy |
title_sort |
routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-hodgkin lymphoma patients undergoing curative-intent r-chop chemotherapy |
publisher |
Public Library of Science (PLoS) |
publishDate |
2018 |
url |
http://scholarbank.nus.edu.sg/handle/10635/142662 |
_version_ |
1800913271705829376 |